Novel HIV Peptides Identified During Treatment Interruption May Inform Next-Generation Therapeutic Strategies
Highlight
– Genetically conserved and mutation-intolerant HIV peptides were detected in rebound virus after analytic treatment interruption (ATI), reinforcing their expression and immunologic relevance in vivo.
– Individuals with transient viral control during ATI showed robust CD8 T-cell responses to these peptides, suggesting their potential as immunotherapeutic targets.
– The findings support the development of mRNA vaccines incorporating these peptides, with preclinical and translational research ongoing.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.